| 36.4346 -0.465 (-1.26%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 43.08 |
1-year : | 43.97 |
| Resists | First : | 36.89 |
Second : | 37.65 |
| Pivot price | 36.45 |
|||
| Supports | First : | 35.66 |
Second : | 29.67 |
| MAs | MA(5) : | 36.95 |
MA(20) : | 36.61 |
| MA(100) : | 34.53  |
MA(250) : | 33.61 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 60.2 |
D(3) : | 70.6 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 37.65 | Low : | 26.86 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ HRTS ] has closed above bottom band by 48.8%. Bollinger Bands are 16.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 36.62 - 36.84 | 36.84 - 37 |
| Low: | 35.78 - 36.08 | 36.08 - 36.3 |
| Close: | 36.05 - 36.48 | 36.48 - 36.81 |
The Tema Heart & Health ETF (HRTS) is designed to strategically invest in companies poised to benefit from cutting-edge developments within the biotechnology and broader healthcare industries. Its investment mandate specifically targets firms focused on advancing treatments and therapies for cardiovascular health, metabolic disorders, and weight management.
Thu, 23 Jul 2026
HRTS ETF Profile: Dividends, Returns (CFI:HRTS) - TradingView
Wed, 27 May 2026
5 Small-cap Biotech ETFs to Watch in 2026 - Investing News Network
Wed, 11 Jun 2025
Weight-Loss Drug ETFs Generate Skinnier Returns Than Expected - The Daily Upside
Wed, 20 Mar 2024
Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss - Investor's Business Daily
Fri, 23 Feb 2024
There's A Problem With Today's Obesity Drugs — How These Companies Are Solving It - Investor's Business Daily
Tue, 21 Nov 2023
A new ETF will allow investors to cash in on the Ozempic-fueled weight loss craze that's swept markets this year - markets.businessinsider.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|